PTC Stock Recent News
PTC LATEST HEADLINES
Productivity improvements help accelerate design workflows and collaboration Faster composite design and manufacturing while maintaining high precision and quality Advanced simulation and AI-driven generative design support earlier product optimization Significantly expanded cable harness design capabilities improve design processes for electrification initiatives BOSTON , June 4, 2025 /PRNewswire/ -- PTC (NASDAQ: PTC) today announced the latest version of its Creo® computer-aided design (CAD) solution, built to help manufacturers deliver their best designs in less time. Creo 12 introduces hundreds of powerful enhancements to its design, simulation, and manufacturing capabilities, enabling teams to work smarter, get more done, and collaborate more effectively.
NEW YORK CITY, NY / ACCESS Newswire / June 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. (“PTC” or the “Company”) (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
NEW YORK , June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
PTC Inc. (PTC) reported earnings 30 days ago. What's next for the stock?
NEW YORK CITY, NY / ACCESS Newswire / May 27, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK , May 26, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ: PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
NEW YORK CITY, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
On the heels of some significant (although potentially temporary) reversals on tariff and trade policy and strong corporate earnings from influential industry leaders, the S&P 500 index has seen a solid recovery over the past six weeks. As of this writing, the benchmark index is now basically flat across 2025's trading.
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of PTC Therapeutics, Inc. ("PTC" or the "Company") (NASDAQ:PTCT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.